Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
International Association for the Treatment of Sexual Offenders medical treatments, or other psychical interventions. Probation supervision and residential placement are not considered treatment for this specific age group. However, they are still important aspects of intervention with juvenile sexual offenders. Family sometimes is a reason as to why juveniles offend. Some characteristics of the family of a juvenile sexual offender are troubled adolescent behavior, environment (can be either advantage or disadvantage neighborhoods, as in both good or both), and also has shown effects such as use of aggression and/or force. When a professional is deciding on a treatment for the adolescent they need to view the adolescent within